ClinicalTrialsFinder
RecruitingPhase 2Phase 3NCT07285850

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD Background: a Dual Arm, Multicenter, Randomized Controlled Study

Sponsor

Eastern Hepatobiliary Surgery Hospital

Enrollment

20 participants

Start Date

Oct 20, 2025

Study Type

INTERVENTIONAL

Conditions

HCC - Hepatocellular Carcinoma

Summary

This research plan involves a treatment approach for advanced hepatocellular carcinoma (HCC) in the context of metabolic-associated steatotic liver disease (MASLD). The study aims to compare the efficacy differences between sequential therapy and concurrent therapy using bevacizumab and atezolizumab for advanced HCC in MASLD. The research will focus on evaluating objective response rates, progression-free survival, disease control rates, and overall survival, while utilizing biomarker analysis to elucidate treatment mechanisms. Additionally, the study will examine treatment safety, including the incidence and severity of adverse events.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This trial is testing a combination of two drugs — bevacizumab and atezolizumab (an immunotherapy) — in people with advanced liver cancer who also have fatty liver disease (a condition known as MASLD). **You may be eligible if...** - You are 18 or older with advanced liver cancer (hepatocellular carcinoma) that cannot be surgically removed - Imaging shows you also have moderate to severe fatty liver disease - You have at least one measurable tumor that has not been irradiated - Your liver, kidney, and blood counts are within acceptable ranges - Your expected survival is at least 3 months - Your performance level is good (ECOG 0–1) **You may NOT be eligible if...** - You do not have fatty liver disease - Your liver cancer is at an early stage and is operable - Your organ function is significantly impaired - You are unwilling to use contraception during the study Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSequential treatment of bevacizumab combined with atezolizumab (sequential group)

The first cycle (3 weeks) receives bevacizumab monotherapy, and from the second cycle onwards, it is combined with atezolizumab until disease progression or intolerable toxicity.

DRUGSimultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Simultaneous treatment of bevacizumab combined with atezolizumab (same period group)

Locations(1)

Eastern Hepatobiliary Surgery Hospital

Shanghai, Shanghai Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07285850

Related Trials

Ipilimumab N01 Combined With Sintilimab, Bevacizumab Biosimilar, and Hepatic Arterial Infusion Chemotherapy as Conversion Therapy for Unresectable Intermediate-Advanced Hepatocellular Carcinoma

NCT075604881 location

A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC

NCT075218521 location

A Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma

NCT073516691 location

Impact of Radiotherapy on ctDNA in Patients With Hepatocellular Carcinoma

NCT068858791 location

A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors

NCT073767071 location